Optimi Health Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University’s Institute for Psychedelic Research
VANCOUVER, BC – May 9, 2024 – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed GMP psychedelics pharmaceutical manufacturer, specializing in controlled substances such as botanical psilocybin and MDMA, is pleased to report a
May 9, 2024
